LY3023414: Clinical Trials

15 trials of LY3023414, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 2 active not recruiting, 2 terminated, 1 available. 7 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 5, Active not recruiting 1, Terminated 1
Phase 27Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1

Follow LY3023414: new trials by email Literature Review of LY3023414 trials Research Report on LY3023414

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
Letrozole, Abemaciclib, LY3023414 - Endometrial Cancer
Phase 2RecruitingDana-Farber Cancer Institute1102018-12-242026-06-22
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)182017-11-282026-04-21
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-11-13
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Abemaciclib, LY3023414, Gemcitabine - Pancreatic Ductal Adenocarcinoma
Phase 2CompletedEli Lilly and Company1062017-01-122019-11-20
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
LY3039478, Taladegib, Abemaciclib - Solid Tumor, Breast Cancer
Phase 1TerminatedEli Lilly and Company942016-11-042025-08-21
A Study of [¹⁴C]-LY3023414 in Healthy Participants
[¹⁴C]-LY3023414 - Healthy
Phase 1CompletedEli Lilly and Company82015-10-012015-11-23
A Study of LY3023414 in Japanese Participants With Advanced Cancer
LY3023414 - Neoplasm
Phase 1CompletedEli Lilly and Company122015-09-012018-07-24
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
LY3023414 - Endometrial Cancer, Recurrent Endometrial Cancer
Phase 2CompletedMemorial Sloan Kettering Cancer Center282015-09-012023-02-22
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
LY3023414, Necitumumab - Non-small Cell Lung Cancer Metastatic
Phase 2TerminatedEli Lilly and Company312015-07-012020-12-09
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
LY3023414, Enzalutamide, Placebo - Prostate Cancer Metastatic
Phase 2CompletedEli Lilly and Company1422015-04-292021-05-11
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Prexasertib, Cisplatin, Cetuximab - Neoplasm Metastasis, Colorectal Neoplasms
Phase 1CompletedEli Lilly and Company1672014-06-182020-04-01
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Abemaciclib, Pemetrexed, Gemcitabine - Carcinoma, Non-small Cell Lung
Phase 1CompletedEli Lilly and Company1422014-03-282020-09-11
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
LY2835219, Letrozole, Anastrozole - Breast Neoplasms
Phase 1Active not recruitingEli Lilly and Company1982014-03-102026-01-26
A Study of LY3023414 in Participants With Advanced Cancer
LY3023414, Midazolam, Fulvestrant - Advanced Cancer, Metastatic Cancer
Phase 1CompletedEli Lilly and Company1562012-07-312022-04-08
Master Rollover Protocol for Continued Safety Assessment of Study Drug
LY2503029, LY3023414, LY3838915 - Cancer
AvailableEli Lilly and Company2026-06-25

Conditions studied

Breast Neoplasms (4)  ·  Lymphoma, Non-Hodgkin (3)  ·  Neoplasms (3)  ·  Sarcoma (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Central Nervous System Neoplasms (2)  ·  Endometrial Neoplasms (2)  ·  Ependymoma (2)  ·  Glioma (2)  ·  Hepatoblastoma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Medulloblastoma (2)  ·  Neoplasm Metastasis (2)  ·  Neuroblastoma (2)  ·  Neuroectodermal Tumors, Primitive, Peripheral (2)

Sponsors

Eli Lilly and Company (11)  ·  National Cancer Institute (NCI) (2)  ·  Dana-Farber Cancer Institute (1)  ·  Memorial Sloan Kettering Cancer Center (1)

Countries

United States (14)  ·  Puerto Rico (3)  ·  Spain (3)  ·  Australia (2)  ·  France (2)  ·  Belgium (1)  ·  Canada (1)  ·  Denmark (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Donald W Parsons (1)  ·  Panagiotis Konstantininopoulos, MD (1)  ·  Theodore W Laetsch (1)  ·  Vicky Makker, MD (1)

Results publications

PMID 24919854, PMID 30082474, PMID 31401903, PMID 33495309, PMID 33591402, PMID 33660194, PMID 33686452, PMID 34559360, PMID 35223458, PMID 35353553, PMID 35363301, PMID 36030462, PMID 36174113, PMID 37840530, PMID 41166674, PMID 42686334

NIH funding

U10CA180886 (2), 2015 (1), 2016 (1)